 |
471 Diseases |  |
207 Trials |
|
207 Trials |  |
10577 News |  |
| «12...106107108109110111112113114115116...132133» |
- metformin / Generic mfg., everolimus / Generic mfg., exemestane / Generic mfg.
Trial primary completion date, Metastases: Exemestane-RAD001-Metformin (clinicaltrials.gov) - Dec 4, 2015
P2, N=40, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Sep 2016 --> Sep 2017
- Avastin (bevacizumab) / Roche
Trial initiation date, Trial primary completion date, Metastases: Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative (clinicaltrials.gov) - Dec 3, 2015
P2, N=37, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Sep 2016 --> Sep 2017 Initiation date: Nov 2015 --> Mar 2016 | Trial primary completion date: Nov 2018 --> Mar 2019
- Halaven (eribulin mesylate) / Eisai
New P1 trial, Combination therapy: Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast Cancers (clinicaltrials.gov) - Nov 30, 2015
P1, N=1, Recruiting, Sponsor: Istituti Ospitalieri di Cremona
- everolimus / Generic mfg., paclitaxel / Generic mfg.
Enrollment change: CROSS: Choice Of Optimal Strategy For Bifurcation Lesions With Normal Side Branch (clinicaltrials.gov) - Nov 22, 2015
P4, N=504, Completed, Sponsor: Seung-Jung Park
Initiation date: Nov 2015 --> Mar 2016 | Trial primary completion date: Nov 2018 --> Mar 2019 N=953 --> 504
- SNX-5422 / Esanex
Trial primary completion date: Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors (clinicaltrials.gov) - Nov 21, 2015
P1, N=15, Recruiting, Sponsor: Esanex Inc.
N=953 --> 504 Trial primary completion date: Oct 2015 --> May 2016
- everolimus / Generic mfg., paclitaxel / Generic mfg.
Trial completion, Enrollment change: CROSS: Choice Of Optimal Strategy For Bifurcation Lesions With Normal Side Branch (clinicaltrials.gov) - Nov 17, 2015
P4, N=953, Completed, Sponsor: Seung-Jung Park
Trial primary completion date: Oct 2015 --> May 2016 Active, not recruiting --> Completed | N=600 --> 953
- everolimus / Generic mfg., sirolimus / Generic mfg., paclitaxel / Generic mfg.
Trial completion, Trial primary completion date: PERFECT: Optimal Stenting Strategy For True Bifurcation Lesions (clinicaltrials.gov) - Nov 17, 2015
P4, N=420, Completed, Sponsor: Seung-Jung Park
Active, not recruiting --> Completed | N=600 --> 953 Active, not recruiting --> Completed | Trial primary completion date: Jan 2015 --> Jun 2015
- Signifor (pasireotide) / Recordati
Phase classification, Trial primary completion date: Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases (clinicaltrials.gov) - Nov 16, 2015
P1, N=13, Active, not recruiting, Sponsor: Emory University
Active, not recruiting --> Completed | Trial primary completion date: Jan 2015 --> Jun 2015 Phase classification: P1/2 --> P1 | Trial primary completion date: Dec 2015 --> Dec 2016
- || Sutent (sunitinib) / Pfizer
Trial primary completion date, Metastases: Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma (clinicaltrials.gov) - Nov 16, 2015
P2, N=108, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Phase classification: P1/2 --> P1 | Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Aug 2016 --> Aug 2017
- ||| everolimus / Generic mfg.
Enrollment closed, Metastases: Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2) (clinicaltrials.gov) - Nov 15, 2015
P4, N=80, Active, not recruiting, Sponsor: iOMEDICO AG
Trial primary completion date: Aug 2016 --> Aug 2017 Recruiting --> Active, not recruiting
- | Avastin (bevacizumab) / Roche
Trial completion, Trial primary completion date: RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma (clinicaltrials.gov) - Nov 15, 2015
P1/2, N=47, Completed, Sponsor: University of Utah
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Jan 2017 --> Aug 2015
- || Kisqali (ribociclib) / Novartis
Trial primary completion date, Combination therapy, Metastases: Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer (clinicaltrials.gov) - Nov 10, 2015
P1/2, N=185, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed | Trial primary completion date: Jan 2017 --> Aug 2015 Trial primary completion date: Nov 2016 --> Jul 2017
- everolimus / Generic mfg., sorafenib / Generic mfg.
Trial initiation date, Trial primary completion date: Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas (clinicaltrials.gov) - Nov 9, 2015
P1/2, N=118, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Nov 2016 --> Jul 2017 Initiation date: Oct 2012 --> Oct 2015 | Trial primary completion date: Oct 2018 --> Jul 2018
- | Herceptin (trastuzumab) / Roche
Enrollment closed, Metastases: Phase II Trial of EVEROLIMUS (clinicaltrials.gov) - Nov 9, 2015
P2, N=34, Active, not recruiting, Sponsor: Emory University
Initiation date: Oct 2012 --> Oct 2015 | Trial primary completion date: Oct 2018 --> Jul 2018 Recruiting --> Active, not recruiting
- ||||| Imbruvica (ibrutinib) / AbbVie, J&J
New P1/2 trial, Combination therapy, Metastases: Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors (clinicaltrials.gov) - Nov 8, 2015
P1/2, N=189, Not yet recruiting, Sponsor: Pharmacyclics
- everolimus / Generic mfg., bendamustine / Generic mfg.
Trial primary completion date: Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer (clinicaltrials.gov) - Nov 5, 2015
P1, N=18, Recruiting, Sponsor: University of California, Davis
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2015 --> May 2016
- ||| everolimus / Generic mfg., fulvestrant / Generic mfg.
Enrollment closed, Metastases: Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI (clinicaltrials.gov) - Oct 30, 2015
P2, N=130, Active, not recruiting, Sponsor: PrECOG, LLC.
Trial primary completion date: Dec 2015 --> May 2016 Recruiting --> Active, not recruiting
- bortezomib / Generic mfg., everolimus / Generic mfg.
Trial termination, Trial primary completion date: Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma (clinicaltrials.gov) - Oct 28, 2015
P1, N=30, Terminated, Sponsor: Brian Hill, MD, PhD
Recruiting --> Active, not recruiting Recruiting --> Terminated | Trial primary completion date: Jun 2015 --> Oct 2015; Treatment ineffective
- Avastin (bevacizumab) / Roche
Trial primary completion date, Metastases: Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer (clinicaltrials.gov) - Oct 27, 2015
P1/2, N=27, Active, not recruiting, Sponsor: University of Southern California
Recruiting --> Terminated | Trial primary completion date: Jun 2015 --> Oct 2015; Treatment ineffective Trial primary completion date: Aug 2015 --> Aug 2016
- ||| davamotecan pegadexamer (EP0057) / Ellipses Pharma
Enrollment closed, Combination therapy, Metastases: CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC) (clinicaltrials.gov) - Oct 23, 2015
P2, N=110, Active, not recruiting, Sponsor: Cerulean Pharma Inc.
Trial primary completion date: Aug 2015 --> Aug 2016 Recruiting --> Active, not recruiting
- | Zokinvy (lonafarnib) / Eiger
New P1/2 trial, P1/2 data, Combination therapy: Phase I/II Trial of Everolimus in Combination With Lonafarnib in Progeria (clinicaltrials.gov) - Oct 23, 2015
P1/2, N=80, Not yet recruiting, Sponsor: Children's Hospital Boston
- | everolimus / Generic mfg.
Enrollment open: SAGE: Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus (clinicaltrials.gov) - Oct 23, 2015
P2, N=43, Recruiting, Sponsor: Fox Chase Cancer Center
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- cisplatin / Generic mfg., everolimus / Generic mfg.
Trial primary completion date: NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer (clinicaltrials.gov) - Oct 22, 2015
P2, N=32, Recruiting, Sponsor: The Methodist Hospital System
Not yet recruiting --> Recruiting Trial primary completion date: Aug 2015 --> Aug 2017
- || everolimus / Generic mfg.
Trial primary completion date: Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer (clinicaltrials.gov) - Oct 22, 2015
P2, N=90, Recruiting, Sponsor: Emory University
Trial primary completion date: Aug 2015 --> Aug 2017 Trial primary completion date: Oct 2015 --> Oct 2016
- ||| Sutent (sunitinib) / Pfizer
Enrollment change, Metastases: Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib (clinicaltrials.gov) - Oct 22, 2015
P4, N=62, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Oct 2015 --> Oct 2016 N=36 --> 62
- everolimus / Generic mfg.
Enrollment open, Metastases: Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations (clinicaltrials.gov) - Oct 22, 2015
P2, N=10, Recruiting, Sponsor: Washington University School of Medicine
N=36 --> 62 Not yet recruiting --> Recruiting
- Caprelsa (vandetanib) / Sanofi
Enrollment change, Combination therapy, Metastases: Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer (clinicaltrials.gov) - Oct 22, 2015
P1, N=174, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting N=118 --> 174
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Trial termination, Trial primary completion date: A Randomised Trial With Irinotecan, Cetuximab and Everolimus (ICE)Compared to Capecitabine and Oxaliplatin (CapOx) for Patients With Gemcitabin Resistant Pancreatic Cancer (clinicaltrials.gov) - Oct 22, 2015
P1/2, N=39, Terminated, Sponsor: Per Pfeiffer
N=118 --> 174 N=90 --> 39 | Not yet recruiting --> Terminated | Trial primary completion date: Jul 2011 --> Nov 2012; Emergence of FOLFIRINOX and slow recruitment
- | Fumena (vorolanib) / Tyrogenex
New P1 trial, Metastases: Study of the Combination of CM082 With Everolimus in Patients With mRCC (clinicaltrials.gov) - Oct 22, 2015
P1, N=18, Recruiting, Sponsor: AnewPharma
- everolimus / Generic mfg.
Enrollment open, Metastases: RAPANK: Study of the Impact of Everolimus Treatment on Lymphocytes NK (Natural Killer) Development and Functions for Patients With a Metastatic Breast Cancer (HR+ / HER2/Neu Negative) (clinicaltrials.gov) - Oct 22, 2015
P=N/A, N=36, Recruiting, Sponsor: Centre Leon Berard
N=90 --> 39 | Not yet recruiting --> Terminated | Trial primary completion date: Jul 2011 --> Nov 2012; Emergence of FOLFIRINOX and slow recruitment Not yet recruiting --> Recruiting
- ||||||| Herceptin (trastuzumab) / Roche
Trial completion, Combination therapy, Metastases: BOLERO-3: Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Oct 15, 2015
P3, N=570, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Avastin (bevacizumab) / Roche
Trial completion, Enrollment change: A Trial of Everolimus and Bevacizumab in Children With Recurrent Solid Tumors (clinicaltrials.gov) - Oct 15, 2015
P1, N=16, Completed, Sponsor: St. Jude Children's Research Hospital
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=24 --> 16
- letrozole / Generic mfg., everolimus / Generic mfg.
Enrollment closed: Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer (clinicaltrials.gov) - Oct 14, 2015
P2, N=20, Active, not recruiting, Sponsor: Mayo Clinic
Active, not recruiting --> Completed | N=24 --> 16 Recruiting --> Active, not recruiting
- everolimus / Generic mfg.
Enrollment closed, Trial primary completion date: Study to Collect and Assess Long-term Safety of Everolimus in Patients Who Are on Everolimus Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator. (clinicaltrials.gov) - Oct 14, 2015
P2, N=2, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2019 --> Jan 2021
- | sotrastaurin (AEB071) / Novartis
Enrollment closed, Enrollment change: COEB071X2103: Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Oct 14, 2015
P1/2, N=31, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2019 --> Jan 2021 Recruiting --> Active, not recruiting | N=70 --> 31
- | Farydak (panobinostat) / Secura Bio, Sutent (sunitinib) / Pfizer
Enrollment closed, Enrollment change, Combination therapy, Metastases: Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate (clinicaltrials.gov) - Oct 9, 2015
P1/2, N=26, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Recruiting --> Active, not recruiting | N=70 --> 31 Recruiting --> Active, not recruiting | N=33 --> 26
- everolimus / Generic mfg.
New P2 trial: EPASOS: Open Label Study of Everolimus (RAD001) in Patients With Segmental Overgrowth Syndrome (clinicaltrials.gov) - Oct 6, 2015
P2, N=18, Not yet recruiting, Sponsor: Jochen Roessler
- || Votrient (pazopanib) / Novartis, BeiGene
Trial primary completion date, Metastases: CATChEz: Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell Carcinoma (clinicaltrials.gov) - Oct 5, 2015
P2, N=70, Recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting | N=33 --> 26 Trial primary completion date: Aug 2015 --> Jan 2016
- Herceptin (trastuzumab) / Roche
Trial primary completion date, Metastases: Phase II Trial of EVEROLIMUS (clinicaltrials.gov) - Oct 5, 2015
P2, N=34, Recruiting, Sponsor: Emory University
Trial primary completion date: Aug 2015 --> Jan 2016 Trial primary completion date: Oct 2015 --> Oct 2016
- everolimus / Generic mfg.
Trial primary completion date, IO biomarker, Metastases: A Biological Prospective Study in Patients With Metastatic Pancreatic NETs Treated With Everolimus (clinicaltrials.gov) - Sep 29, 2015
P2, N=47, Recruiting, Sponsor: European Institute of Oncology
Trial primary completion date: Oct 2015 --> Oct 2016 Trial primary completion date: Jun 2015 --> Jun 2016
- |||| everolimus / Generic mfg.
Enrollment open, Combination therapy: LEVER: Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer (clinicaltrials.gov) - Sep 25, 2015
P2, N=270, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jun 2015 --> Jun 2016 Not yet recruiting --> Recruiting
- | New P2 trial: Personalized Targeted Inhibitors Treatment in Renal Cell Cancer (clinicaltrials.gov) - Sep 25, 2015
P2, N=100, Not yet recruiting, Sponsor: The University of Texas Health Science Center, Houston
- |||| everolimus / Generic mfg.
Trial completion, Metastases: RECORD-4: Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma (clinicaltrials.gov) - Sep 24, 2015
P2, N=135, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- everolimus / Generic mfg.
Trial completion, Enrollment change, Metastases: Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer (clinicaltrials.gov) - Sep 24, 2015
P2, N=11, Completed, Sponsor: Translational Oncology Research International
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=50 --> 11
- | everolimus / Generic mfg.
Enrollment closed, Enrollment change: EXIST-LT: Long-term Monitoring of Growth and Development of Pediatric Patients Previously Treated With Everolimus (clinicaltrials.gov) - Sep 24, 2015
P4, N=15, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed | N=50 --> 11 Recruiting --> Active, not recruiting | N=65 --> 15
- Avastin (bevacizumab) / Roche
Trial primary completion date, Metastases: Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma (clinicaltrials.gov) - Sep 22, 2015
P2, N=149, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Recruiting --> Active, not recruiting | N=65 --> 15 Trial primary completion date: Mar 2020 --> Dec 2014
- everolimus / Generic mfg.
Trial initiation date, Metastases: Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations (clinicaltrials.gov) - Sep 21, 2015
P2, N=10, Not yet recruiting, Sponsor: Washington University School of Medicine
Trial primary completion date: Mar 2020 --> Dec 2014 Initiation date: Jun 2015 --> Oct 2015
- everolimus / Generic mfg., sirolimus / Generic mfg.
Enrollment open: Conversion From Sirolimus to Everolimus in the Maintenance Treatment of Liver Transplant Recipients (clinicaltrials.gov) - Sep 14, 2015
P=N/A, N=70, Recruiting, Sponsor: Ege University
Initiation date: Jun 2015 --> Oct 2015 Not yet recruiting --> Recruiting
- Trial primary completion date: A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer (clinicaltrials.gov) - Sep 8, 2015
P1, N=24, Recruiting, Sponsor: Fox Chase Cancer Center
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2014 --> Dec 2015
- | Farydak (panobinostat) / Secura Bio, Sutent (sunitinib) / Pfizer
Enrollment change, Combination therapy, Metastases: Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate (clinicaltrials.gov) - Sep 8, 2015
P1/2, N=33, Recruiting, Sponsor: Roswell Park Cancer Institute
Trial primary completion date: Dec 2014 --> Dec 2015 N=48 --> 33